Systematic review of vonoprazan as <italic style="font-style: italic">Helicobacter pylori</italic> eradication therapy

ZHANG Mengran; PANG Mingge; ZHAI Huihong

doi:10.6039/j.issn.1001-0408.2023.05.19

您当前的位置：

首页 >

文章列表页 >

Systematic review of vonoprazan as Helicobacter pylori eradication therapy

更新时间：2023-06-12

- Systematic review of vonoprazan as Helicobacter pylori eradication therapy
- ZHONGGUO YAOFANG Vol. 34, Issue 5, Pages: 613-619(2023)
- 作者机构：
  
  1.首都医科大学宣武医院消化内科，北京　100053
  2.北京市普仁医院内科，北京　100062
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.05.19
  CLC： R975
- Published：15 March 2023，
  
  Received：14 September 2022，
  
  Revised：29 January 2023，
扫描看全文
张梦然,庞铭歌,翟惠虹.伏诺拉生用于幽门螺杆菌根除治疗的系统评价[J].中国药房,2023,34(05):613-619.

ZHANG Mengran,PANG Mingge,ZHAI Huihong.Systematic review of vonoprazan as Helicobacter pylori eradication therapy[J].ZHONGGUO YAOFANG,2023,34(05):613-619.
张梦然,庞铭歌,翟惠虹.伏诺拉生用于幽门螺杆菌根除治疗的系统评价[J].中国药房,2023,34(05):613-619. DOI： 10.6039/j.issn.1001-0408.2023.05.19.

ZHANG Mengran,PANG Mingge,ZHAI Huihong.Systematic review of vonoprazan as Helicobacter pylori eradication therapy[J].ZHONGGUO YAOFANG,2023,34(05):613-619. DOI： 10.6039/j.issn.1001-0408.2023.05.19.

摘要

目的

系统评价伏诺拉生（VPZ）用于幽门螺杆菌（Hp）根除治疗的有效性和安全性，为临床治疗Hp感染提供参考。

方法

计算机检索The Cochrane Library、Embase、PubMed、中国知网、维普网和万方数据等，检索时限为建库起至2022年7月。收集VPZ根除治疗（试验组）且以质子泵抑制剂（PPI）作为对照（对照组）的随机对照试验，提取资料并采用Cochrane系统评价手册5.1.0推荐的偏倚风险评估工具进行质量评价，使用RevMan 5.3软件进行Meta分析。

结果

共纳入9项研究、合计2 134例患者。在意向治疗（ITT）分析和符合方案（PP）分析中，试验组患者的Hp总体根除率均较对照组显著升高，分别为87.5% vs. 76.2%[RR＝1.14，95%CI（1.06，1.21），

＜0.001]和92.4% vs. 80.5%[RR＝1.11，95%CI（1.03，1.21），

＜0.01]。在初始治疗亚组的ITT和PP分析中，试验组患者的Hp总体根除率均较对照组显著升高，分别为88.4% vs. 76.5%[RR＝1.15，95%CI（1.09，1.22），

＜0.000 01]和92.8% vs. 80.9%[RR＝1.12，95%CI（1.03，1.23），

＜0.05]；在补救治疗亚组的ITT和PP分析中，两组患者的Hp总体根除率比较差异均无统计学意义（

＞0.05）。在三联疗法亚组ITT和PP分析中，试验组患者的Hp总体根除率均较对照组显著升高，分别为88.3% vs. 75.6%[RR＝1.16，95%CI（1.08，1.25），

＜0.000 1]和92.6% vs. 77.6%[RR＝1.15，95%CI（1.04，1.28），

＜0.01]；在四联疗法亚组ITT和PP分析中，两组患者的Hp总体根除率比较差异均无统计学意义（

＞0.05）。试验组患者的总体不良事件发生率较对照组显著降低，分别为34.2% vs. 40.9%[RR＝0.84，95%CI（0.70，0.99），

＜0.05]；两组患者的严重不良事件发生率比较差异无统计学意义（

＞0.05）。

结论

与PPI疗法比较，含VPZ的三联治疗方案效果更优，尤其对于初治患者而言；但在补救治疗及含铋剂四联方案中，VPZ无显著优势。含VPZ抗Hp治疗方案的安全性及耐受性良好，甚至优于PPI。

Abstract

OBJECTIVE

To systematically evaluate the efficacy and safety of vonoprazan （VPZ） for

Helicobacter pylori

（Hp） eradication therapy.

METHODS

Retrieved from The Cochrane Library， Embase， PubMed， CNKI， VIP and Wanfang database， randomized controlled trials about VPZ for Hp eradication therapy （trial group） versus proton pump inhibitor （PPI）（control group） were collected during the inception to July 2022. After data extraction and quality evaluation with bias risk assessment tool recommended by Cochrane System Evaluation Manual 5.1.0， meta-analysis was performed by using RevMan5.3 software.

RESULTS

Nine studies with 2 134 patients were included. Compared with control group， the overall Hp eradication rate of trial group increased significantly in either the ITT analysis or PP analysis， being 87.5% vs. 76.2% [RR＝1.14， 95%CI （1.06，1.21），

＜0.001] and 92.4% vs. 80.5% [RR＝1.11， 95%CI （1.03，1.21），

＜0.01]， respectively. According to ITT and PP analysis of primary treatment subgroup， compared with control group， the overall Hp eradication rate of trial group increased significantly， being 88.4% vs. 76.5% [RR＝1.15， 95%CI （1.09，1.22），

＜0.000 01] and 92.8% vs. 80.9% [RR＝1.12， 95%CI（1.03，1.23），

＜0.05]； according to ITT and PP analysis of rescue therapy subgroup， there was no significant difference in the overall Hp eradication rate between control group and trial group （

＞0.05）. According to ITT and PP analysis of triple therapy subgroup， compared with control group， overall Hp eradication rate of trial group increased significantly， being 88.3% vs. 75.6% [RR＝1.16， 95%CI （1.08， 1.25），

＜0.000 1] and 92.6% vs. 77.6% [RR=1.15， 95%CI （1.04， 1.28），

＜0.01]； according to ITT and PP analysis of quadruple therapy subgroup， there was no significant d

ifference in the overall Hp eradication rate between control group and trial group （

＞0.05）. Compared with control group， the incidence of adverse events in trial group decreased significantly， being 34.2% vs. 40.9% [RR＝0.84， 95%CI（0.70，0.99），

＜0.05]. There was no statistical significance in the incidence of serious adverse events between 2 groups （

＞0.05）.

CONCLUSIONS

Compared with PPI therapy， the efficacy of VPZ-based triple therapy is better， particularly in primary treatment patients. However， VPZ has no significant advantage in rescue treatment and bismuth-containing quadruple regimen. And the safety and tolerance of VPZ for Hp eradication therapy are well， even better than PPI.

关键词

幽门螺杆菌伏诺拉生质子泵抑制剂根除治疗Meta分析

Keywords

vonoprazanproton pump inhibitorseradication therapymeta-analysis

references

HOOI J K Y，LAI W Y，NG W K，et al. Global prevalence of Helicobacter pylori infection：systematic review and meta-analysis[J]. Gastroenterology，2017，153（2）：420-429.

MALFERTHEINER P，MEGRAUD F，O'MORAIN C A，et al. Management of Helicobacter pylori infection：the Maastricht V/Florence consensus report[J]. Gut，2017，66（1）：6-30.

Sugano Kentaro，Tack Jan，Kuipers Ernst J，et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut，2015，64：1353-67.

SUGANO K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer：a systematic review and meta-analysis[J]. Gastric Cancer，2019，22（3）：435-445.

LEE J Y，PARK K S. Optimal first-line treatment for Helicobacter pylori infection：recent strategies[J]. Gastroenterol Res Pract，2016，2016：9086581.

Hunfeld N G，Touw D J，Mathot R A，et al. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism[J]. Aliment Pharmacol Ther，2012，35：810-8.

JUNG Y S，KIM E H，PARK C H. Systematic review with meta-analysis：the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication[J]. Aliment Pharmacol Ther，2017，46（2）：106-114.

SHINOZAKI S，KOBAYASHI Y，OSAWA H，et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy：systematic review and meta-analysis[J]. Digestion，2021，102（3）：319-325.

BUNCHORNTAVAKUL C，BURANATHAWORNSOM A. Randomized clinical trial：7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori[J]. J Gastroenterol Hepatol，2021，36（12）：3308-3313.

HOJO M，ASAOKA D，TAKEDA T，et al. Randomized controlled study on the effects of triple therapy including vonoprazan or rabeprazole for the second-line treatment of Helicobacter pylori infection[J]. Therap Adv Gastroenterol，2020，13：1756284820966247.

HOU X H，MENG F D，WANG J B，et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients[J]. J Gastroenterol Hepatol，2022，37（7）：1275-1283.

HUH K Y，CHUNG H，KIM Y K，et al. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication[J]. Br J Clin Pharmacol，2022，88（1）：138-144.

MARUYAMA M，TANAKA N，KUBOTA D，et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication：a randomized controlled trial[J]. Can J Gastroenterol Hepatol，2017，2017：4385161.

MURAKAMI K，SAKURAI Y，SHIINO M，et al. Vonoprazan，a novel potassium-competitive acid blocker，as a component of first-line and second-line triple therapy for Helicobacter pylori eradication：a phase Ⅲ，randomised，double-blind study[J]. Gut，2016，65（9）：1439-1446.

SUE S，OGUSHI M，ARIMA I，et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori：a multicenter，prospective，randomized trial[J]. Helicobacter，2018，23（2）：e12456.

SUE S，SHIBATA W，SASAKI T，et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori[J]. J Gastroenterol Hepatol，2019，34（4）：686-692.

TAMAKI H，NODA T，MORITA M，et al. 437：an open-label，multi-center，randomized，superiority trial of vonoprazan versus esomeprazole as part of first-line triple therapy for Helicobacter pylori infection[J]. Gastroentero- logy，2019，156（6）：S-89.

CHEY W D，LEONTIADIS G I，HOWDEN C W，et al. ACG clinical guideline：treatment of Helicobacter pylori infection[J]. Am J Gastroenterol，2017，112（2）：212-239.

KATO M，OTA H，OKUDA M，et al. Guidelines for the management of Helicobacter pylori infection in Japan：2016 revised edition[J]. Helicobacter，2019，24（4）：e12597.

VILLORIA A，GARCIA P，CALVET X，et al. Meta-analysis：high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication[J]. Aliment Pharmacol Ther，2008，28（7）：868-877.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of ivabradine on vascular endothelial function in patients with coronary artery disease： a meta-analysis

Meta-analysis about ADRB1 Arg389Gly polymorphism on the efficacy of bisoprolol

Meta-analysis of efficacy and safety of aspirin versus other anticoagulants in the prevention of thromboembolism after orthopedic surgery

Meta-analysis of the efficacy and safety of Saccharomyces boulardii versus Bifidobacterium triple live bacteria in the treatment of pediatric diarrhea

Systematic review and meta-analysis of health state utility for global patients with hemophilia

Related Author

CHEN Congling

YANG Xian

WU Han

YING Jiachen

ZHANG Ruobin

LAN Xi

ZHANG Jinping

ZHANG Tianqi

Related Institution

Dept. of Cardiology， Nanjing Drum Tower Hospital

School of Basic Medicine and Clinical Pharmacy， China Pharmaceutical University

Dept. of Pharmacy， Nanjing Drum Tower Hospital

Dept. of Pharmacy， Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine， Chinese Academy of Medical Science/Beijing Key Laboratory of Assessment for Clinical Risk and Individual Application of Drugs

Dept. of Cardiology， General Hospital of Eastern Theater Command

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Systematic review of vonoprazan as Helicobacter pylori eradication therapy

DOI：10.6039/j.issn.1001-0408.2023.05.19

摘要

Abstract

关键词

Keywords

references